Boehringer Testing Copy of Rituxan in Type of LymphomaAndrea Gerlin
Boehringer Ingelheim GmbH started testing a version of Roche Holding AG’s top-selling drug Rituxan for non-Hodgkin’s lymphoma, broadening the possible uses the German company sees for its copy of the medicine.
Boehringer is already recruiting patients in another trial of the drug in rheumatoid arthritis and adding an indication in non-Hodgkin’s lymphoma, a type of cancer, may help increase sales, Asthika Goonewardene, a London-based analyst for Bloomberg Industries, said in a note to clients today.
“Boehringer’s efficient clinical program may generate the data required to file for regulatory approval in both the U.S. and EU for the two key indications which account for more than 90 percent of Rituxan sales,” Goonewardene wrote.
Boehringer is seeking to enter a crowded field of potential competitors. Novartis AG, Celltrion Inc., partners Samsung Electronics Co. and Quintiles Transnational Corp., and Teva Pharmaceutical Industries Ltd. with Lonza Group AG are among the companies already working on a Rituxan copy. Some of the companies have had setbacks in developing a Rituxan copy, Goonewardene wrote.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Comedian Byron Allen Buys the Weather Channel for $300 Million
- Stocks Tumble in Biggest Weekly Decline Since 2016: Markets Wrap
- Musk Takes Down the Tesla and SpaceX Facebook Pages
- Stocks Drop Most in Six Weeks on Trade War Tension: Markets Wrap
- World's Biggest Cryptocurrency Exchange Is Heading to Malta